TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33736601
Drug: 45 ml
Normalized name: ethanol 0.645 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 ml 40 °C lukewarm water
Study: 33592607
Drug: Topical glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticoids (TGC)
Study: 36075079
Drug: Weight-based enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based enoxaparin dosing (0.5 mg/kg every 12 hours)
Study: 36075079
Drug: Fixed-dose enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose enoxaparin (40 mg daily for BMI < 40; 40 mg every 12 hours for BMI ≥ 40)
Study: 35490599
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg for 2 weeks
Study: 33346091
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy to the prostate bed (51 Gy in 15 fractions, 3.4 Gy per fraction)
Study: 34250911
Drug: Single Bond
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Bond Universal Agent (Group A)
Study: 34250911
Drug: Seal &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seal & Protect Agent (Group B)
Study: 33815533
Drug: α-viniferin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-viniferin administered three times a day for ten days using a sterile cotton swab stick.
Study: 33622079
Drug: Chemical bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical bleaching with 40% hydrogen peroxide (H2O2) gel
Study: 33622079
Drug: 40% H2O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% H2O2 gel activated with the diode laser
Study: 33446440
Drug: Pompage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pompage therapy (24 sessions over 8 weeks, 40 minutes each, three times a week)
Study: 33514367
Drug: Kaloba® tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaloba® tablet
Study: 32720353
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation therapy (OAT) continued
Study: 32401715
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta‐1b on alternate days for 14 days)
Study: 32401715
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lopinavir 400 mg and ritonavir 100 mg every 12 h for 14 days)
Study: 34209647
Drug: Self-guided forest
Normalized name: Fortesta
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-guided forest therapy
Study: 34209647
Drug: Guided forest
Normalized name: Fortesta
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided forest therapy program
Study: 36253714
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg GTN administered in the catheter immediately after recanalization
Study: 36253714
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered in the catheter immediately after recanalization
Study: 35788622
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (20 mg/d on days 1-5, then 10 mg/d on days 6-10)
Study: 35788622
Drug: Standard dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dexamethasone (6 mg/d for 10 days)
Study: 32472620
Drug: Alcohol beverage
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol beverage sufficient to produce a breath alcohol concentration of 0.08 g/dl
Study: 33256237
Drug: Cell-based therapy
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-based therapy
Study: 32311473
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg intravenous linezolid
Study: 32311473
Drug: 900- and
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 900- and 1200-mg linezolid doses
Study: 32311473
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the standard dose of linezolid
Study: 35802209
Drug: Mindfulness intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness intervention in conjunction with behavioral treatment (BT)
Study: 35802209
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (BT) active control condition
Study: 36501158
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg BM of glucose (Glu)
Study: 36501158
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg BM of fructose (Fru)
Study: 36501158
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg BM of glucose/fructose (GluFru)
Study: 36501158
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g sucralose (placebo)
Study: 35908116
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (16 sessions)
Study: 35347281
Drug: Topical B‐VEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical B‐VEC treatment
Study: 32419310
Drug: High bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bicarbonate dialysate concentration (36 mmol/L)
Study: 32419310
Drug: Bicarbonate dialysate
Normalized name: Duosol Bicarbonate Dialysate 2-Chamber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate dialysate concentration of 30 mmol/L (Control)
Study: 36420538
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of Pregnancy Category (PC) letters in drug labeling
Study: 36420538
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of Pregnancy Category (PC) letters in drug labeling
Study: 32469870
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement from pre-conception to term (PC-T)
Study: 32469870
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement from mid-gestation to term (MG-T)
Study: 34476629
Drug: M1 a‐tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: M1 a‐tDCS concurrent with physical therapy (PT) for 10 sessions of 20 minutes each
Study: 34476629
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group received sham tDCS concurrent with physical therapy (PT) for 10 sessions of 20 minutes each
Study: 34476629
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only physical therapy (PT) for 10 sessions of 20 minutes each
Study: 33958657
Drug: Weekly iron-folic
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron-folic acid supplementation (WIFAS)
Study: 36070638
Drug: Solriamfetol 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 37.5 mg/day (OSA only), 75 mg/day, 150 mg/day, 300 mg/day
Study: 36070638
Drug: Solriamfetol (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol (combined doses)
Study: 35217575
Drug: Single-agent ieramilimab
Normalized name: Ieramilimab
DrugBank: Ieramilimab (DB16419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent ieramilimab
Study: 35217575
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ieramilimab and spartalizumab
Study: 34518266
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment with standard glycaemic control
Study: 34518266
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment with standard glycaemic control
Study: 34518266
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment with intensive glycaemic control
Study: 34518266
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment with intensive glycaemic control
Study: 34518266
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment for those with cognitive impairment
Study: 34518266
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment for those with cognitive impairment
Study: 34518266
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment for those with normal cognitive function
Study: 34518266
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment for those with normal cognitive function
Study: 32915300
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 20 mL of 0.375% levobupivacaine
Study: 32915300
Drug: Retrolaminar block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrolaminar block (RLB) with 20 mL of 0.375% levobupivacaine
Study: 32140719
Drug: Seabuckthorn oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seabuckthorn oil augmented in 16:1n-7t (480 mg 16:1n-7t/d)
Study: 32140719
Drug: Unmodified seabuckthorn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmodified seabuckthorn oil (1520 mg 16:1n-7c/d)
Study: 36239033
Drug: Aripiprazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (2 mg/day, adjusted to 1-10 mg/day)
Study: 32940187
Drug: Tocilizumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (monoclonal antibody against IL-6 receptors)
Study: 37815091
Drug: High Protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Protein Diet via Whey Protein Supplementation (PRO, 2 × 25 g whey protein isolate/d)
Study: 37815091
Drug: Control (CON,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (CON, 2 × 23.75 g maltodextrin/d)
Study: 33683019
Drug: Peramivir 600
Normalized name: peramivir 600 mg in 60 mL INTRAVENOUS SOLUTION [Rapivab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peramivir 600 mg repeat-dose
Study: 33683019
Drug: Peramivir 300
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Peramivir 300 mg single-dose
Study: 35465686
Drug: MK‐7 (720
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐7 (720 µg) plus vitamin D (25 µg)
Study: 34791634
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide extended-release (TA-ER) 32 mg
Study: 34849957
Drug: Sofosbuvir/daclatasvir 400/60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir/daclatasvir 400/60 mg once-daily
Study: 32674048
Drug: 15‐mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐mg oral methotrexate per week
Study: 32674048
Drug: 3–5‐mg/kg/day cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3–5‐mg/kg/day cyclosporine
Study: 33934389
Drug: Resveratrol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (1000 mg/day)
Study: 36181304
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day placebo
Study: 36181304
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day melatonin
Study: 36181304
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day melatonin plus 30 min of bright light therapy (BLT)
Study: 35700691
Drug: Bilastine 20
Normalized name: Bilastine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilastine 20 mg under fasting conditions
Study: 35700691
Drug: Bilastine 20
Normalized name: Bilastine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilastine 20 mg under fed conditions
Study: 33189179
Drug: Progestogen-only pill
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen-only pill (75 μg desogestrel) plus a rapid access card to a sexual and reproductive health clinic
Study: 32975923
Drug: Neurofascial dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofascial dextrose prolotherapy (8 mL of 12.5% dextrose and 40 mg of 2% lidocaine, injected 2 times with 1-week interval)
Study: 34939872
Drug: Training in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training in coping skills and coping with stress self-efficacy (15 sessions, twice per week for 8 weeks)
Study: 34939872
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy (control group)
Study: 32949140
Drug: Seletalisib 45
Normalized name: Seletalisib
DrugBank: Seletalisib (DB12706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seletalisib 45 mg/day
Study: 33412997
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) started from 40% of MIP, given in addition to a neurodevelopmental treatment program for 5 days a week for 6 weeks
Study: 33412997
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IMT), received the same neurodevelopmental treatment program
Study: 35729759
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg oral dose)
Study: 34158376
Drug: Serratus block
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratus block (ropivacaine 0.5%; 20 mL unilateral; 16 mL/side bilateral)
Study: 34158376
Drug: Paravertebral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral block (ropivacaine 0.5%; 20 mL unilateral; 16 mL/side bilateral)
Study: 32183769
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behaviour therapy (ICBT) with a comprehensive pre-treatment assessment interview
Study: 32183769
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behaviour therapy (ICBT) with guidance from a health educator
Study: 32183769
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behaviour therapy (ICBT) without pre-treatment assessment interview
Study: 32183769
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behaviour therapy (ICBT) without guidance from a health educator
Study: 33636418
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of fish oil ω‐3 fatty acids daily
Study: 33636418
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of fish oil n‐3 fatty acids and 500 mL of reduced‐calorie cranberry juice daily
Study: 34639600
Drug: FIBROWALK plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIBROWALK plus Treatment-As-Usual (TAU)
Study: 32323706
Drug: Probiotics administration
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics administration
Study: 33736696
Drug: Early ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early ART initiation (within 2 weeks after anti-CMV therapy)
Study: 33736696
Drug: Deferred ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred ART initiation (more than 2 weeks after anti-CMV therapy)
Study: 35320643
Drug: Hydrocortisone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (4 mg per kilogram of body weight per day tapered over a period of 10 days)
Study: 34787240
Drug: Adjuvant low‐laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant low‐laser light therapy
Study: 34787240
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (topical and compressive treatment)
Study: 35697890
Drug: Intensified medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified medical therapy
Study: 33236860
Drug: Incisional negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative pressure wound therapy (INPWT) applied after primary closure of the midline sternotomy (n = 52)
Study: 33236860
Drug: Incisional negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative pressure wound therapy (INPWT)
Study: 33782092
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence management intervention
Study: 34924513
Drug: Antigravity treadmill
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antigravity treadmill therapy
Study: 32198963
Drug: TAP catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP catheter group (TAP-C) infused with 0.2% ropivacaine at 10 mL/h
Study: 32198963
Drug: TAP saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP saline group (TAP-S) infused with saline at 10 mL/h
Study: 32747302
Drug: Fluoropyrimidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoropyrimidine plus bevacizumab as maintenance treatment
Study: 32747302
Drug: Fluoropyrimidine alone
Normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluoropyrimidine alone as maintenance treatment
Study: 33449848
Drug: Inorganic nitrate
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic nitrate supplementation (4.03 mmol nitrate and 0.29 mmol nitrite daily for 4 weeks)
Study: 32887850
Drug: Self-efficacy intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-efficacy intervention (six weekly individual physical therapy sessions for lower-extremity exercise and fitness walking; nine biweekly nurse telephone counseling sessions)
Study: 32887850
Drug: Attention-control intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Attention-control intervention (six weekly and nine biweekly nurse telephone sessions on health topics)
Study: 34245081
Drug: HepB-alum vaccine
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: HepB-alum vaccine
Study: 34245081
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HepB-alum vaccine)
Study: 32112114
Drug: remifentanil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil (3 μg/kg) + propofol (2.5 mg/kg)
Study: 32112114
Drug: sufentanil (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil (0.3 μg/kg) + propofol (2.5 mg/kg)
Study: 36214061
Drug: 2% minoxidil
Normalized name: MINOXIDIL 2 g in 100 mL TOPICAL LIQUID [2% Minoxidil hair growth serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% minoxidil combined with microneedling (weekly)
Study: 36214061
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (microneedling + minoxidil)
Study: 34482089
Drug: CAC-disclosed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAC-disclosed group (atorvastatin treatment)
Study: 33609618
Drug: Structured clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured clinical algorithm for scheduled counselling, glucose monitoring, and adjustment of medication
Study: 33176772
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health assessment using WHO Oral Health Assessment form 1997 and WHO oral health assessment questionnaire for adult/children 2013
Study: 33176772
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of treatment needs
Study: 35131037
Drug: Semaglutide 1·7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 1·7 mg
Study: 34099328
Drug: IHV01 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHV01 vaccine (75 µg, 150 µg, and 300 µg doses)
Study: 34099328
Drug: IHV01 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHV01 vaccine
Study: 32419935
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral dexamethasone 0.3 mg/kg (maximum 12 mg)
Study: 32419935
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone 0.6 mg/kg/day for 2 days (maximum 16 mg/day)
Study: 32419935
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 1.5 mg/kg/day for 5 days (maximum 60 mg/day)
Study: 34156758
Drug: Spray-on skin
Normalized name: benzethonium Topical Spray [New-Skin Liquid Bandage]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-on skin (ReCell)
Study: 32737577
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (2.5 mg on two successive days a week)
Study: 32737577
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (up to 2 g for 180 days)